Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure

Acta Oncologica

Volumn 54, Issue 9, 2015, Pages 1355-1363

  Zschaeck, Sebastian ^a,b   Haase, Robert ^a   Abolmaali, Nasreddin ^a   Perrin, Rosalind ^a,c   Stützer, Kristin ^a   Appold, Steffen ^a   Steinbach, Jörg ^d   Kotzerke, Jörg ^a,b,d   Zips, Daniel ^a,b,e   Richter, Christian ^a,b,d   Gudziol, Volker ^a   Krause, Mechthild ^a,b,d   Zöphel, Klaus ^a,b   Baumann, Michael ^a,b,d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; MITOMYCIN; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXIA; IMAGE ANALYSIS; MALE; MIDDLE AGED; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; TREATMENT FAILURE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANOXIA; CARCINOMA, SQUAMOUS CELL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFORMAL RADIOTHERAPY; CONTROLLED STUDY; HEAD AND NECK NEOPLASMS; INTENSITY MODULATED RADIATION THERAPY; MULTIMODAL IMAGING; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING;

ANOXIA; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MISONIDAZOLE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84955698322     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1074720     Document Type: Article

References (36)

1. Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol 2012; 22: 108-18.
2. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-9.
4. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012; 9: 674-87.
5. Yaromina A, Thames H, Zhou X, Hering S, Eicheler W, Dörfler A, et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010; 96: 116-22.
6. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
7. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417-28.
8. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol 2012; 105: 14-20.
9. Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, et al. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010; 37: 2048-59.
10. Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-60.
11. Thorwarth D, Eschmann S-M, Paulsen F, Alber M. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007; 68: 291-300.
12. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011; 101: 369-75.
13. Hoeben BAW, Bussink J, Troost EGC, Oyen WJG, Kaanders JHAM. Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol 2013; 52: 1257-71.
14. Rischin D, Peters LJ, OSullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28: 2989-95.
15. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys 2008; 70: 2-13.
16. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009; 50: 1020-7.
17. Chang JH, Wada M, Anderson NJ, Lim Joon D, Lee ST, Gong SJ, et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: A biological modeling study. Acta Oncol 2013; 52: 1723-9.
18. Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 70: 235-42.
19. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 2013; 54: 201-7.
20. Bittner M-I, Wiedenmann N, Bucher S, Hentschel M, Mix M, Weber WA, et al. Exploratory geographical analysis of hypoxic subvolumes using (18)F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol 2013; 108: 511-6.
21. Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012; 105: 21-8.
22. Budach V, Becker E-T, Boehmer D, Badakhshi H, Jahn U, Wernecke K-D, et al. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial. Strahlenther Onkol 2014; 190: 250-5.
23. 18F]FMISO-PET in HNSCC. When is the contrast best? Nukl Nucl Med 2011; 50: 22-7.
24. Hofheinz F, Pötzsch C, Oehme L, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nukl Nucl Med 2012; 51: 9-16.
25. Crum WR, Camara O, Hill DLG. Generalized overlap measures for evaluation and validation in medical image analysis. IEEE Trans Med Imaging 2006; 25: 1451-61.
26. Muijs CT, Schreurs LM, Busz DM, Beukema JC, van der Borden AJ, Pruim J, et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiother Oncol 2009; 93: 447-53.
27. Haase R, Böhme H-J, Zips D, Abolmaali N. Swarm intelligence for medical volume segmentation: The contribution of self-reproduction. In: Bach J, Edelkamp S., editors. KI 2011: Advances in artificial intelligence. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 111-21.
28. H. Johnson, Y. Zhao. BRAINSDemonWarp: An application to perform demons registration. Insight J 2009;Jan-Jun.
29. Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J-C, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 2012; 30: 1323-41.
30. Haase R, Abolmaali, N. A modular software system for image analysis in positron emission tomography. Workshop on Tomography, data processing and image reconstruction for medicine and engineering. 2012; Helmholtz-Zentrum Dresden-Rossendorf, Dresden.
31. Sterpin E, Differding S, Janssens G, Geets X, Grégoire V, Lee JA. Generation of prescriptions robust against geometric uncertainties in dose painting by numbers. Acta Oncol 2015; 54: 253-60.
32. Alber M, Thorwarth D. Multi-modality functional image guided dose escalation in the presence of uncertainties. Radiother Oncol 2014; 111: 354-9.
33. Henriques de Figueiredo B, Merlin T, de Clermont-Gallerande H, Hatt M, Vimont D, Fernandez P, et al. Potential of [(18)F]-Fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas. Strahlenther Onkol 2013; 189: 1015-9.
34. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997; 147: 541-50.
35. Schütze C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Zips D, et al. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. Radiother Oncol 2014; 111: 81-7.
36. Due AK, Vogelius IR, Aznar MC, Bentzen SM, Berthelsen AK, Korreman SS, et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 2014; 111: 360-5.